CD95 (APO-/
Fas) ligand (
CD95L) is a member of the TNF family predominantly expressed by activated T and NK cells but also by
tumors of diverse cellular origin.
CD95L trimerizes surface CD95 expressed by target cells that subsequently undergo apoptosis. The role of the CD95/
CD95L system in the down-regulation of an immune response (activation-induced cell death) is established. However, it is so far unclear why
tumors express
CD95L. To investigate whether
tumors use the
CD95L to down-regulate an anti-
tumor immune response, we established a transgenic (tg) mouse model consisting of 1) apoptosis-resistant
tumor cells, designated LKC-
CD95L, which express functional
CD95L and the model
tumor Ag K(b); and 2)
perforin knockout (PKO) anti-K(b) TCR tg mice. L1210-Fas antisense expressing K(b), crmA, and
CD95L (LKC-
CD95L) killed CD95(+) unrelated
tumor targets and Con A-activated splenocytes from anti-K(b) TCR tg PKO mice by a
CD95L-dependent mechanism in vitro. However, we could not detect any cytotoxic activity against anti-
tumor (anti-K(b)) T cells in vivo. We also observed reduced growth of LKC-
CD95L in nude mice and rapid rejection in anti-K(b) TCR tg PKO mice. Because the
tumor cells are resistant to
CD95L-,
TNF-alpha-, and
TNF-related apoptosis-inducing ligand-induced apoptosis and the mice used are
perforin-deficient, the involvement of these four cytotoxicity mechanisms in
tumor rejection can be excluded. The histological examination of
tumors grown in nude mice showed infiltration of LKC-
CD95L tumors by neutrophils, whereas L1210-Fas antisense expressing K(b) and crmA (LKC)
tumor tissue was neutrophil-free. Chemotaxis experiments revealed that
CD95L has no direct neutrophil-attractive activity. Therefore, we conclude that LKC-
CD95L cells used an indirect mechanism to attract neutrophils that may cause
tumor rejection.